$61.050
-1.349 (-2.21%)At close
IONS News
IONS Events
Trump Considers New Semiconductor Tariffs Impacting Multiple Companies
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.SEMICONDUCTOR TARIFFS:The Trump administration is considering broad new semiconductor tariffs that could extend to chip-containing products such as laptops and data-center servers, potentially raising AI infrastructure costs while linking tariff relief to U.S. manufacturing investment, Politico's Ari Hawkins and Gabby Miller. The administration is also mulling a phase-in period for the new tariffs, people familiar with the matter say. Publicly traded companies in the space include AMD, Intel, Marvell, Microchip, Micron, Nvidia, Qualcommand Texas Instruments.GRID EQUIPMENT:President Trump signed an emergency order that bars the U.S. purchase or installation of certain foreign-made, bulk-power system electrical equipment, and associated software, where it could pose cybersecurity or operational risks, Jennifer Dlouhy of Bloomberg, citing a White House official. Publicly traded companies in the solar space include Array Technologies, Canadian Solar, Emeren, Enphase Energy, FTC Solar, First Solar, JinkoSolar, Maxeon Solar, Shoals Technologies, SolarEdge, SunPowerand Sunrun.DRUG PRICING DEALS:The Trump administration is set to announce new drug pricing agreements with several midsized biotechs, trading Medicaid discounts tied to international prices for exemptions from certain Medicare pricing pilots and, in some cases, tariff relief, Bloomberg's Nyah Phengsitthy, Rachel Cohrs Zhang, and Madison Muller. Publicly traded companies in the space include Neurocrine Biosciences, Exelixis, Alnylam, BioMarin, United Therapeutics, Ionis, Bio-Techne, and Alkermes.DATA-SHARING DEALS:The Trump administration has struck data-sharing deals with OpenAI, Google, Meta, Amazon, and other tech companies to track how AI is affecting jobs and hiring, Courtenay Brown of Axios. The Labor Department has signed memorandums of understanding with "a lot of these tech companies," acting Labor Secretary Keith Sonderling told Axios.
Ionis Pharmaceuticals to Present New Data at ESC Congress
Ionis Pharmaceuticals announced that new data in the management of severe hypertriglyceridemia, sHTG, will be presented at the European Society of Cardiology, ESC, Congress 2026, taking place August 28 - 31 in Munich. Presentations include one-year data from the open-label, long-term extension study of Tryngolza, recently approved in the U.S. as the first and only treatment for sHTG to reduce triglycerides and the risk of acute pancreatitis, and Phase 1 data in hypertriglyceridemia for ION775, an investigational siRNA and next-generation follow-on to Tryngolza with the potential for semiannual or less frequent dosing.
Ionis Pharmaceuticals Chief Scientific Officer Frank Bennett to Retire in February 2027
Ionis Pharmaceuticals announced that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective February 2027. Dr. Bennett will serve as a strategic consultant for a period after his retirement to support the transition. His responsibilities will be assumed by Eric Swayze, Ph.D., executive vice president, head of research.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.